Grant: Strategic Projects - Group
University of Toronto
$133,600.00
Ultrasensitive multiplexed mass cytometry immunoassays based on single patch nanoparticles
FY 2011-12
Summary
This proposal describes research on the synthesis of inorganic nanoparticles (NPs), particularly lanthanide-containing nanoparticles, and their conjugation to monoclonal antibodies. The NP-antibody complexes are designed for quantitative cellular immunoassays of biomarkers and transcripts of low copy number. The analysis of low copy number biomarkers on a cell-by-cell basis is of fundamental interest in cell biology and provides an important new diagnostic for cell based diseases such as cancer. Bioassays with NP-antibody conjugates take advantage of the multiplexing capabilities of mass cytometry, a new technique developed by DVS Sciences, Richmond Hill ON, based upon the union of atomic mass spectrometry and cytometry. Current methods using the DVS mass cytometer are able to detect biomarker expression at the level of ~2000 per cell using antibody tags carrying ~200 ions of a lanthanide isotope. To achieve the high sensitivity needed to detect biomarkers at the level of <100 copies per cell, the nanoparticles must contain atleast 5000 atoms of a single metal isotope. This requires NPs with diameters of 10 to 15 nm, comparable in size to the antibodies themselves. This proposal explores new synthetic strategies for conjugating antibodies to lanthanide nanoparticles. For quantitative mass cytometry, each antibody against a specific biomarker should be bound by a separate NP. To ensure the antibodies do not crosslink the antigens we will explore the potential of confining reactive functional groups to a small patch on the surface of the NPs, with the goal of ensuring that only a small number (1-4) of antibodies will be attached to each inorganic nanoparticle. Metal NP conjugates will be evaluated by mass cytometry for use in quantifying both high and low surface biomarker expression on leukemia cells. Then we will quantify intracellular antigens such as the oncoprotein p53 which is expressed at variable levels dramatically affecting cell physiology. Once realized these NP-antibody conjugates will be useful for the diagnosis, monitoring and hopefully, to find cures for complex human diseases such as cancer, viral infections such as AIDS, metabolic disorders, and heart disease.
Program
Strategic Projects - Group
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
397120-2010
Name nom
Winnik, Mitchell
Department département
Chemistry
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2011
Competition year année de concours
2010
Award amount
133600
Program id
STPGP
Program nane en
Strategic Projects - Group
Program name fr
Projets stratégiques - De groupe
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1088
Committee name en
Strategic Projects Selection Panel - Manufacturing - B
Committee name fr
Comité de sélection des projets stratégiques - Fabrication - B
Area of application code
602
Area of application group en
Construction, urban and rural planning
Area of application group fr
Construction, urbanisme et aménagement rural
Area of application en
Materials performance
Area of application fr
Performance des matériaux
Research subject code
6400
Research subject group en
Life sciences research related to human health and disease
Research subject group fr
Sciences de la vie liées à la santé publique et aux maladies humaines
Research subject en
Life sciences research related to human health and disease
Research subject fr
Sciences de la vie liées à la santé publique et aux maladies humaines
Partie
2
Nb partie
3
Application title
Ultrasensitive multiplexed mass cytometry immunoassays based on single patch nanoparticles
Keyword
NSERC
Application summary
This proposal describes research on the synthesis of inorganic nanoparticles (NPs), particularly lanthanide-containing nanoparticles, and their conjugation to monoclonal antibodies. The NP-antibody complexes are designed for quantitative cellular immunoassays of biomarkers and transcripts of low copy number. The analysis of low copy number biomarkers on a cell-by-cell basis is of fundamental interest in cell biology and provides an important new diagnostic for cell based diseases such as cancer. Bioassays with NP-antibody conjugates take advantage of the multiplexing capabilities of mass cytometry, a new technique developed by DVS Sciences, Richmond Hill ON, based upon the union of atomic mass spectrometry and cytometry. Current methods using the DVS mass cytometer are able to detect biomarker expression at the level of ~2000 per cell using antibody tags carrying ~200 ions of a lanthanide isotope. To achieve the high sensitivity needed to detect biomarkers at the level of <100 copies per cell, the nanoparticles must contain atleast 5000 atoms of a single metal isotope. This requires NPs with diameters of 10 to 15 nm, comparable in size to the antibodies themselves. This proposal explores new synthetic strategies for conjugating antibodies to lanthanide nanoparticles. For quantitative mass cytometry, each antibody against a specific biomarker should be bound by a separate NP. To ensure the antibodies do not crosslink the antigens we will explore the potential of confining reactive functional groups to a small patch on the surface of the NPs, with the goal of ensuring that only a small number (1-4) of antibodies will be attached to each inorganic nanoparticle. Metal NP conjugates will be evaluated by mass cytometry for use in quantifying both high and low surface biomarker expression on leukemia cells. Then we will quantify intracellular antigens such as the oncoprotein p53 which is expressed at variable levels dramatically affecting cell physiology. Once realized these NP-antibody conjugates will be useful for the diagnosis, monitoring and hopefully, to find cures for complex human diseases such as cancer, viral infections such as AIDS, metabolic disorders, and heart disease.